ArticleJournal of comparative effectiveness research2023
Access in all areas? A round up of developments in market access and health technology assessment: part 2.
Article in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 27.Journal of comparative effectiveness research · 2026Review
- Access in all areas? A round-up of developments in market access and health technology assessment: part 14.Journal of comparative effectiveness research · 2026Review
- Access in all areas? A round-up of developments in market access and health technology assessment: part 13.Journal of comparative effectiveness research · 2026Article
- Access in all areas? A round up of developments in market access and health technology assessment: part 8.Journal of comparative effectiveness research · 2025Article
- R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.Journal of comparative effectiveness research · 2025Article
- Access in all areas? A round up of developments in market access and health technology assessment: part 7.Journal of comparative effectiveness research · 2025Article
- The need to consider market access for pharmaceutical investment decisions: a primer.Journal of comparative effectiveness research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.